氟达拉滨方案改善混合表型急性白血病生存:基于WHO 2022分类的人群研究
该全国性队列研究纳入43例经WHO 2022分类验证的强化治疗混合表型急性白血病(MPAL)患者,比较ALL样、AML样及混合方案对完全缓解(CR)、总生存(OS)和无事件生存(EFS)的影响。混合方案CR率最高(87.5%),含氟达拉滨的混合方案较经典柔红霉素-阿糖胞苷AML方案显著改善OS和EFS(p=0.02和p=0.002)。
要点
- 混合方案CR率87.5%,ALL方案72%,AML方案40%。
- 含氟达拉滨混合方案较经典AML方案改善OS(p=0.02)和EFS(p=0.002)。
- 研究基于丹麦全国病理登记库并按WHO 2022分类验证。
核心结论
- 含氟达拉滨的混合方案治疗MPAL与更优的OS和EFS相关。
研究设计与样本
- 全国性人群研究,通过丹麦国家病理登记库识别并经WHO 2022分类验证的43例强化治疗MPAL患者。
- 采用Kaplan-Meier法估计OS,log-rank检验比较OS差异,逆概率加权平衡年龄和日历年。
主要发现
- 43例中25例(58.1%)接受ALL方案,10例(23.3%)接受AML方案,8例(18.6%)接受混合方案。
- 混合方案CR率87.5%(95%CI:47.3%-99.7),ALL方案72%(95%CI:50.6%-87.5),AML方案40%(95%CI:12.2%-73.8)。
- 含氟达拉滨混合方案(FLAG-IDA、Mito-FLAG或FLEGMA)较经典柔红霉素-阿糖胞苷AML方案改善OS(p=0.02)和EFS(p=0.002)。
关键数值与推荐
- 混合方案CR率87.5%(95%CI:47.3%-99.7),ALL方案72%(95%CI:50.6%-87.5),AML方案40%(95%CI:12.2%-73.8)。
- 含氟达拉滨混合方案对比经典AML方案:OS差异p=0.02,EFS差异p=0.002。
临床怎么用
- 对强化治疗的MPAL患者,可优先考虑含氟达拉滨的混合方案以改善缓解率和生存。
局限性
- 样本量小(43例),混合方案组仅8例,置信区间宽。
- 为人群登记研究,非随机对照设计,可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mixed phenotype acute leukaemia (MPAL) is a rare subtype of acute leukaemia possessing significant therapeutic challenges, as no standardized, evidence-based treatment regimen has been defined. In this nationwide study, we aimed to assess the effect of an acute lymphoid leukaemia (ALL)-like regimen; an acute myeloid leukaemia (AML)-like regimen; and a hybrid regimen on complete remission (CR), overall survival (OS) and event-free survival (EFS). Patients were identified through the Danish National Pathology Registry and validated according to the 2022 WHO classification. OS was estimated using the Kaplan-Meier estimator, and differences in OS were assessed with the log-rank test. Inverse probability weighting was used to balance compared groups with respect to age and calendar year. Among the 43 intensively treated WHO 2022 MPAL patients, 25 (58.1%) received ALL regimens, 10 (23.3%) received AML regimens and 8 (18.6%) received hybrid regimens. CR rates by treatment regimen were highest for hybrid regimen (87.5% (95% confidence interval (CI): 47.3%-99.7)), followed by ALL regimen (72% (95% CI: 50.6%-87.5%)) and AML regimen (40% (95% CI: 12.2%-73.8%)). Treatment with hybrid regimens consisting of a fludarabine-based approach (fludarabine, cytarabine, G-CSF and idarubicin [FLAG-IDA], fludarabine, cytarabine, G-CSF and mitoxantrone [Mito-FLAG] or fludarabine, etoposide, G-CSF, mitoxantrone and cytarabine [FLEGMA]) was associated with improved OS and EFS compared to a classic daunorubicin-cytarabine AML regimen (p = 0.02 and p = 0.002 respectively).
引用
- Christensen LM, Simonsen MR, Jensen JF, et al. Improved survival with fludarabine-based therapies in mixed phenotype acute leukaemia: A population-based study using the WHO 2022 classification. Br J Haematol. 2026. PMID: 41992976. doi:10.1111/bjh.70491
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。